JCB, Volume 10, Number 4, 2004 Editorial Vol.10 No. 4 (2004) Editorial: R&D in biotechnology – The management challenges Simon Shohet   Article Vol.10 No. 4 (2004) 2003: What lessons for European biotechnology? M S Fazeli The biotech sector had a sizzling year last year, raising US$19bn in cash globally. This paper looks at the performance of the biotechnology sector on both sides of the Article Vol.10 No. 4 (2004) Biotechnology's special forces: Field-based medical science liaisons Jane Chin Biotechnology companies with a product commercialisation strategy are deploying field-based medical science liaisons (MSLs) to increase awareness of a therapeutic marke Article Vol.10 No. 4 (2004) The class of 2004: Human capital in biotechnology David Collingham This paper assesses growth models for biotechnology organisations, comparing the dynamics of company evolution in the previous decade with circumstances pertinent to th Article Vol.10 No. 4 (2004) Encouraging industry participation in the EU's Sixth Framework Programme: Issues, barriers and potential solutions Wills Hughes-Wilson There is around 100m annually in the Sixth Framework Programme earm Article Vol.10 No. 4 (2004) Biotech–pharma alliances: Strategies, structures and financing Tyzoon Tyebjee The drug discovery and development industry is under intense pressure to become more efficient and develop drugs better, faster, cheaper. Consequently, pharmaceutical a Article Vol.10 No. 4 (2004) Biotechnology policy in European countries: An assessment Bernhard Zechendorf For more than 20 years, all major European governments have put biotechnology as a priority on their innovation policy agendas. How did each of the three big countries Article Vol.10 No. 4 (2004) Singapore's biomedical science sector development strategy: Is it sustainable? Lisa P L Lim This paper outlines the strategic efforts undertaken by Singapore to establish its national capability in the biomedical science sector, reviews the commercial base as Article Vol.10 No. 4 (2004) The market of therapeutic recombinant proteins to 2010 Alex K Pavlou Datamonitor's recombinant protein analytical framework shows that the sector with 77 marketed and 104 pipeline products will reach maturity undisturbed from potential b Legal and Regulatory Updates Vol.10 No. 4 (2004) Legal and regulatory update John Wilkinson The Competitiveness Council of Ministers met last month to discuss the outstanding issues concerning translation of patents in the proposed community patent regime. A y Legal and Regulatory Updates Vol.10 No. 4 (2004) EU financial accounts reports Colin Aaronson Acambis is a profitable and cash-generative biotechnology company that is focused on building a substantial franchise in the vaccine space. Its results for the period h